Compare Icl Group Ltd (ICL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Travere Therapeutics Inc. Common Stock — how do they compare? Icl Group Ltd trades at $4.99 (market cap $6.47B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Icl Group Ltd is the larger of the two by market cap, and Icl Group Ltd pays a 4.12% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| ICL | TVTX | |
|---|---|---|
Market Cap | $6.47B | $5.02B |
Volume | 1,473,067 | 2,060,842 |
Sector | Basic Materials | Health |
52-Week High | $6.80 | $67.52 |
52-Week Low | $4.80 | $26.79 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $9.10B | $5.15B |
Dividend Yield | 4.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $4.98, up 0.81% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $0.12, beating expectations, but revenue and net income have declined from 2022 peaks. Valuation ratios appear reasonable with P/E of 20.75 and P/B of 1.05. All four covering analysts maintain Hold ratings with a $6.08 consensus target, suggesting 22% upside potential.
The outlook remains cautious due to industry headwinds and declining profitability, though the dividend yield provides some support. Key risks include fertilizer market volatility and execution of the cost-transformation program. The stock offers value but requires monitoring of operational improvements and market conditions for sustained recovery.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
